Interleukin-18 (IL-18), originary called interferon (IFNγ )-inducing factor, is a recently cloned cytokine of approximately 18 kDa. Its major activity is the induction of IFNγ production from anti-CD3-activated Thl cells, especially in the presence of IL-12. Recently, the human IL-18 cDNA was cloned and expressed in Escherichia coli [1] . It has been revealed that human IL-18 has the capacity to stimulate cytotoxic natural killer (NK) cell activity and stimulates T-cells to produce IFNγ , IL-2, and granulocyte/ macrophage colony-stimulating factor [1] . It is reported that IL-18 is produced by Kupfer cells, activated macrophages, keratinocytes, intestinal epithelial cells, osteoblasts, adrenal cortex cells and murine dincephalon [2, 3] .
Taniguchi et al. reported that the IL-18 levels from two groups of acute lymphocytic leukemia (ALL) and chronic myelocytic leukemia (CML) patients is significantly increased compared to the control group [4] . We evaluated the serum IL-18 levels in patients with multiple myeloma (MM), myelodysplastic syndrome (MDS), acute non-lymphocytic leukemia (ANLL), ALL, aplastic anemia (AA), idiopathic thrombocytopenic purpura (ITP), Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), adult T-cell leukemia (ATL), CML and hemophagocytic syndrome (HPS) in this study. On entry all patients had evidence of active disease and had not received previous therapy. The human serum concentration of IL-18 was measured using an enzyme-linked immunoabsorbent assay kit for IL-18 (MBL, * To whom correspondence should be addressed. Dr. T. Takubo, Department of Clinical and Laboratory Medicine, Osaka City University Medical School, 1-4-3, Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
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Nagoya, Japan) [4] . In the 9 healthy volunteers, the reference value of serum IL-18 was 100 ± 22.8 pg/ ml (mean ± SD). The serum IL-18 levels in patients with various hematological disorders are summarized in Table 1 . As shown in Table 1 , the serum IL-18 concentration in hematological disorders showed a high tendency compared to that in healthy volunteers. The serum IL-18 levels were markedly elevated (> 2000 pg/ ml) in 2 patients with ATL and HPS, and were moderately elevated (500-1000 pg/ ml) in 4 patients with MDS, HD, ALL and ANLL and were moderately elevated (300-500 pg/ ml) in eight patients with ITP, ANLL, CML, NHL, AA and MDS. These data suggest that IL-18 may be produced in excess by activated macrophages in HPS, and by tumor cells as tumor-associated protein in hematological malignancies of ATL, ANLL, ALL, NHL, HD, MDS and CML, and that the level of this cytokine is somewhat elevated in AA and ITP. Determination of the 
